Cas:29070-92-6 Pachymic acid manufacturer & supplier

Chemical Name:Pachymic acid

CAS.NO:29070-92-6

Synonyms:pachimic acid;Lanost-8-en-21-oic acid, 3-(acetyloxy)-16-hydroxy-24-methylene-, (3β,16α)-;3-O-Acetyltumulosic acid;3-ACETYLTUMULOSIC ACID;Lanost-8-en-21-oic acid,3-(acetyloxy)-16-hydroxy-24-methylene-,(3beta,16alpha);(3β,16α)-3-Acetoxy-16-hydroxy-24-methylenelanost-8-en-21-oic acid;Pachymasaeure;(3b,16a)-3-(Acetyloxy)-16-hydroxy-24-methylenelanost-8-en-21-oic acid;Lanost-8-en-21-oic acid,3-(acetyloxy)-16-hydroxy;pachymaic acid

Molecular Formula:C₃₃H₅₂O₅

Molecular Weight:528.763

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:612.2±55.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.540

PSA:83.83000

Exact Mass:528.381470

LogP:8.59

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like pachimic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pachymaic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Lanost-8-en-21-oic acid, 3-(acetyloxy)-16-hydroxy-24-methylene-, (3β,16α)- Use and application,Pachymasaeure technical grade,usp/ep/jp grade.

Related News: Also, states with higher obesity rates also tend to have higher rates of food insecurity, which means lower incomes in general,” she noted. “Bariatric surgery is an expensive proposition, especially if one does not have good insurance coverage for it. Pachymic acid manufacturer The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. Pachymic acid supplier An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant. Pachymic acid vendor The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. Pachymic acid factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.